By Adam Pick on September 11, 2018
There are LOTS of great advances happening in the treatment of heart valve disease. Many of those technological breakthroughs enable cardiologists and surgeons to perform life-saving procedures with smaller-and-smaller incisions.
As you might recall, one of the big breakthroughs in valve therapy was the FDA approval of the da Vinci Surgical System to perform robotic mitral valve repair procedures for patients with mitral valve regurgitation in 2002. Since then, we have collectively learned a lot about robotic surgery from leading clinicians including Drs. Chitwood, Trento, Gillinov, Mihaljevic and Badhwar.
Recently, I’ve received several great questions about robotic mitral valve surgery. For that reason, I felt it was time to get an update about robotic technology. I wanted an expert opinion, so I reached out Dr. T. Sloane Guy at Weill Cornell Medicine in New York City. Dr. Guy is a robotic specialist that has helped many patients from our patient community. Here are the highlights from our recent exchange.
By Adam Pick on August 29, 2018
On behalf of our patient community, I want to extend a mighty thanks to Dr. Allan Stewart at the Miami Cardiac & Vascular Institute for becoming our newest sponsor!!!
As you may know, Dr. Stewart is a long-time supporter of the HeartValveSurgery.com community. In addition to performing successful surgery on over 300 patients from our community at Mount Sinai Hospital and Columbia University Medical Center, Dr. Stewart has helped me create many educational stories and videos. He’s also an endurance athlete that runs triathlons and marathons with his patients – like Gregg O’Keeffe.
By Adam Pick on August 21, 2018
Great questions are coming in from our patient community about the use of transcatheter aortic valve replacement (TAVR) for the treatment of bicuspid aortic valves. If you didn’t know, TAVR is a non-invasive approach to aortic valve replacement that does not require an incision to the patient’s sternum or ribs. TAVR was approved by the FDA in 2011 for “high risk” patients. In 2016, the FDA approved TAVR for “intermediate risk” patients. Recently, clinical trials have launched to test the safety and efficacy of TAVR in “low risk” patients.
By Adam Pick on August 9, 2018
In case you missed it… The INSPIRIS RESILIA heart valve is now available in the United States. This is an important development for patients who require a more resilient tissue valve for the replacement of their native or prosthetic aortic valve.^
This revolutionary aortic valve (pictured below) is the first in a new class of so-called resilient heart valves introduced by Edwards Lifesciences. It has a new tissue that is better at blocking calcium and a first of its kind expandable valve frame designed for potential future valve-in-valve procedures.*^ And it is built on the proven Carpentier-Edwards PERIMOUNT valve design – which has helped over one million patients worldwide.
By Adam Pick on July 25, 2018
Now, more than ever, I am getting questions about atrial fibrillation (AFib) from heart valve patients. And, for good reason. Did you know that up to 35% of patients with heart valve disease have AFib? And, did you know that people with AFib are 5 times more likely to have a stroke? Sadly, did you know that AFib can result in heart failure?
On top of all that… Did you know that AFib is commonly IGNORED during heart valve surgery? Watch this new video to learn the shocking realities of AFib treatment for valve patients, the latest AFib research, and the most effective AFib treatment options from Dr. Harold Roberts, a leading heart surgeon at West Virginia University Medical Center.
I really want (need) to over-emphasize the key points made by Dr. Roberts in this interview: